Followers | 130 |
Posts | 14996 |
Boards Moderated | 1 |
Alias Born | 06/04/2018 |
![](https://investorshub.advfn.com/uicon/675392.png?cb=1562414338)
Tuesday, November 26, 2019 7:00:25 PM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Evercore ISI 2 nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 1:15 pm ET at the Four Se...
Got this from ALNY - Alnylam to Webcast Presentations at Upcoming December Investor Conferences
Recent ALNY News
- Alnylam présente les résultats détaillés de l'étude de phase 3 HELIOS-B positive de Vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie au congrès de la Société européenne de cardiologie • Business Wire • 08/30/2024 08:03:00 PM
- Alnylam präsentiert detaillierte Ergebnisse der positiven HELIOS-B-Phase-3-Studie mit Vutrisiran▼ bei Patienten mit ATTR-Amyloidose mit Kardiomyopathie auf dem Kongress der Europäischen Gesellschaft für Kardiologie • Business Wire • 08/30/2024 05:10:00 PM
- Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress • Business Wire • 08/30/2024 10:00:00 AM
- Alnylam to Webcast Presentations at Upcoming September Investor Conferences • Business Wire • 08/28/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 12:01:25 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 09:10:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:07:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:10:22 PM
- Europäischer Kardiologenkongress 2024: Alnylam legt detaillierte Ergebnisse der Phase-3-Studie HELIOS-B zu Vutrisiran▼ bei ATTR-Amyloidose mit Kardiomyopathie vor • Business Wire • 08/08/2024 02:08:00 AM
- Alnylam présentera des résultats détaillés de l'étude HELIOS-B de phase 3 pour le vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie lors du congrès 2024 de la Société européenne de cardiologie • Business Wire • 08/07/2024 11:04:00 PM
- Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 • Business Wire • 08/07/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/06/2024 08:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2024 12:01:26 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:01:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 12:22:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:11:34 PM
- Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity • Business Wire • 08/01/2024 12:00:00 PM
- Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results • Business Wire • 07/18/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/13/2024 12:02:23 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 08:40:50 PM
- Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations • Business Wire • 06/24/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:00:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:34:56 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM